About Us

Zimbabwe health workers receive PPE from donors

About Us

Who we are

The Clinton Health Access Initiative (CHAI) is a global health organization that operates at the nexus of government, business, and health. Our approach hinges on our trusted relationships with governments to drive change across entire health systems.

Our vision

A world in which everyone is able to live a healthy and fulfilling life.

Our mission

To save lives and improve health outcomes in low- and middle-income countries by enabling the government and private sector to strengthen and sustain quality health systems.

Our values

We are a mission-driven organization.

We work in cooperation with and at the service of partner governments.

We work with urgency.

We foster diversity, equity, and inclusion.

We operate on trust and transparency.

We have an entrepreneurial and action-oriented culture.

We operate with humility.

We recognize our staff is our greatest asset.

We are frugal.

Our History

CHAI was founded in 2002 with a transformational goal: help save the lives of millions of people living with HIV/AIDS. Today, we support government priorities across many areas, including other infectious diseases, non-communicable diseases, women and children’s health, health workforce and financing, assistive technologies for disabilities, and the intersection of climate and health.

2002- 2003

CHAI’s first program: HIV/AIDS

First programs begin in Africa and the Caribbean, aimed at scaling up HIV/AIDS care and treatment in entire countries. 800,000 people are treated in these countries in five years as a result of this work, up from a total of 2,000 when the work began.

First programs begin in Africa and the Caribbean, aimed at scaling up HIV/AIDS care and treatment in entire countries. 800,000 people are treated in these countries in five years as a result of this work, up from a total of 2,000 when the work began.

Alt text

2003

HIV first-line agreement

CHAI negotiates lower prices for first-line HIV drugs by over 60 percent, enabling over 60 countries to access the new prices.

CHAI negotiates lower prices for first-line HIV drugs by over 60 percent, enabling over 60 countries to access the new prices.

Alt text

2003

ART program in South Africa

CHAI begins work with South Africa to scale up treatment, laying the foundation for the largest antiretroviral therapy (ART) program in the world.

CHAI begins work with South Africa to scale up treatment, laying the foundation for the largest antiretroviral therapy (ART) program in the world.

2004- 2005

Pediatric HIV treatment

CHAI leads global effort alongside Unitaid to scale up treatment for children with AIDS in 34 countries, from around 75,000 on treatment to over 900,000 today, lowering the price of medications from over US$600 to around US$60 per child, per year.

CHAI leads global effort alongside Unitaid to scale up treatment for children with AIDS in 34 countries, from around 75,000 on treatment to over 900,000 today, lowering the price of medications from over US$600 to around US$60 per child, per year.

2005- 2007

HIV second-line agreement

CHAI works with Unitaid to negotiate agreements to lower the price of second-line HIV/AIDS treatments by 75 percent and accelerate the roll out of these drugs to over 30 countries where patients were failing on first-line treatments.

CHAI works with Unitaid to negotiate agreements to lower the price of second-line HIV/AIDS treatments by 75 percent and accelerate the roll out of these drugs to over 30 countries where patients were failing on first-line treatments.

2007

Expansion into malaria

CHAI launches a malaria program, which grows rapidly to help government partners increase funding to combat malaria, improve access to quality diagnosis and treatment, and support evidence-based decision making to target resources and accelerate progress toward elimination.

CHAI launches a malaria program, which grows rapidly to help government partners increase funding to combat malaria, improve access to quality diagnosis and treatment, and support evidence-based decision making to target resources and accelerate progress toward elimination.

2009

Scale-up HIV care and treatment in South Africa

CHAI assists the government of South Africa with the largest scale-up of HIV care and treatment ever attempted, from 800,000 people in 2009 to approximately three million today. CHAI helps negotiate agreements to lower HIV and TB drug prices that save the South African government almost US$1 billion.

CHAI assists the government of South Africa with the largest scale-up of HIV care and treatment ever attempted, from 800,000 people in 2009 to approximately three million today. CHAI helps negotiate agreements to lower HIV and TB drug prices that save the South African government almost US$1 billion.

2010

Effective drugs to treat malaria

CHAI increases access to artemisinin-based combination therapies (ACTs). Over two years, we help get almost 300 million ACTs to patients in eight countries.

CHAI increases access to artemisinin-based combination therapies (ACTs). Over two years, we help get almost 300 million ACTs to patients in eight countries.

2011

Expansion into vaccines

CHAI begins work to lower costs and increase access to vaccines. Alongside the Bill & Melinda Gates Foundation, CHAI negotiates a landmark agreement to lower the price of the GSK rotavirus vaccine by 67 percent and the Biological E. Limited pentavalent vaccine by 50 percent, saving the global community over US$800 million and US$150 million respectively. The pentavalent vaccine averted an estimated 2.6 million deaths from 2011-2015.

CHAI begins work to lower costs and increase access to vaccines. Alongside the Bill & Melinda Gates Foundation, CHAI negotiates a landmark agreement to lower the price of the GSK rotavirus vaccine by 67 percent and the Biological E. Limited pentavalent vaccine by 50 percent, saving the global community over US$800 million and US$150 million respectively. The pentavalent vaccine averted an esti...

2011

MATCH study launch

CHAI, with support from the Bill & Melinda Gates Foundation, conducts the Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH) with the governments of Ethiopia, Malawi, Rwanda, South Africa, and Zambia, using evidence to inform debate on affordability and sustainability of universal access to treatment. As a result, an additional 443,000 patients are eligible for treatment.

CHAI, with support from the Bill & Melinda Gates Foundation, conducts the Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH) with the governments of Ethiopia, Malawi, Rwanda, South Africa, and Zambia, using evidence to inform debate on affordability and sustainability of universal access to treatment. As a result, an additional 443,000 patients are eligible for treatment.

2011

Expansion into human resources for health

CHAI helps the government of Rwanda establish a world-class health system through educating doctors, nurses, and health managers. CHAI eventually expands this work to other countries including Liberia, Malawi, and Zambia.

CHAI helps the government of Rwanda establish a world-class health system through educating doctors, nurses, and health managers. CHAI eventually expands this work to other countries including Liberia, Malawi, and Zambia.

2012

Human resources for health in Zambia

CHAI begins working with the Zambian government to educate large groups of community health assistants who are then deployed to villages across the country to bring high-quality healthcare to people with limited access.

CHAI begins working with the Zambian government to educate large groups of community health assistants who are then deployed to villages across the country to bring high-quality healthcare to people with limited access.

2012

Long-acting reversible contraception

CHAI and partners, including the Bill & Melinda Gates Foundation, the United Kingdom’s Department for International Development, United States Agency for International Development, NORAD, Children’s Investment Fund Foundation, and the Swedish International Development Cooperation Agency, negotiate an agreement to lower the price of Bayer and Merck’s long-acting reversible contraceptives from US$18 to US$8.50 per implant and accelerate roll-out of the products to save the lives of women.

CHAI and partners, including the Bill & Melinda Gates Foundation, the United Kingdom’s Department for International Development, United States Agency for International Development, NORAD, Children’s Investment Fund Foundation, and the Swedish International Development Cooperation Agency, negotiate an agreement to lower the price of Bayer and Merck’s long-acting reversible contraceptives from U...

2013

Improving severe malaria testing and treatment

CHAI works to lower the cost and increase the availability of injectable artesunate, a malaria medicine that can dramatically decrease malaria mortality, particularly in children. CHAI also worked with global manufacturers and importers in Tanzania’s private sector to reduce the price of malaria Rapid Diagnostic Tests (RDTs) by 50 to 70 percent.

CHAI works to lower the cost and increase the availability of injectable artesunate, a malaria medicine that can dramatically decrease malaria mortality, particularly in children. CHAI also worked with global manufacturers and importers in Tanzania’s private sector to reduce the price of malaria Rapid Diagnostic Tests (RDTs) by 50 to 70 percent.

2013

Treating childhood diarrhea

CHAI begins work to reduce mortality from diarrhea for children under five, scaling up access to lifesaving zinc/ORS treatment in India, Kenya, Nigeria, and Uganda. CHAI supports governments to lower the cost of zinc/ORS products, resulting in wholesale prices dropping by approximately 60 percent.

CHAI begins work to reduce mortality from diarrhea for children under five, scaling up access to lifesaving zinc/ORS treatment in India, Kenya, Nigeria, and Uganda. CHAI supports governments to lower the cost of zinc/ORS products, resulting in wholesale prices dropping by approximately 60 percent.

2014

Ebola response in Liberia

CHAI, with the support of the Norwegian Government, helps lead case management and health worker training in response to the Ebola crisis in Liberia, serving as a critical link between the international emergency response and the Liberian government.

CHAI, with the support of the Norwegian Government, helps lead case management and health worker training in response to the Ebola crisis in Liberia, serving as a critical link between the international emergency response and the Liberian government.

2014

Introducing new products to treat childhood diarrhea

CHAI helps introduce more than 15 new high-quality, affordable zinc and ORS products, including co-packaged products, into local markets in CHAI partner countries. The increased market competition leads to wholesale prices being reduced by 40 to 75 percent.

CHAI helps introduce more than 15 new high-quality, affordable zinc and ORS products, including co-packaged products, into local markets in CHAI partner countries. The increased market competition leads to wholesale prices being reduced by 40 to 75 percent.

A neonate in an incubator sleeps while receiving supplemental oxygen.

2015

Expansion into new programs

CHAI introduces new programs in hepatitis, pneumonia, and cancer.

CHAI introduces new programs in hepatitis, pneumonia, and cancer.

A neonate in an incubator sleeps while receiving supplemental oxygen.

2015- 2016

Reducing mother and infant deaths in Nigeria

CHAI introduces a comprehensive community-based approach to save mothers and newborns in Northern Nigeria through improved outreach, treatment, and training of health workers, resulting in a sustained 37 percent reduction in maternal deaths, a 43 percent reduction in newborn deaths, and a 15 percent reduction in stillbirths within 12 months.

CHAI introduces a comprehensive community-based approach to save mothers and newborns in Northern Nigeria through improved outreach, treatment, and training of health workers, resulting in a sustained 37 percent reduction in maternal deaths, a 43 percent reduction in newborn deaths, and a 15 percent reduction in stillbirths within 12 months.

2016

Lowering the cost of hepatitis C treatment

CHAI helps reduce the cost of hepatitis C treatment in seven countries by 71 to 95 percent, from US$2,618 per patient to between US$133 and US$789 per patient treated.

CHAI helps reduce the cost of hepatitis C treatment in seven countries by 71 to 95 percent, from US$2,618 per patient to between US$133 and US$789 per patient treated.

2016

Ethiopia develops first-of-its-kind medical oxygen roadmap in Africa

While many countries later followed suite, CHAI's support to implement this in the years before the COVID-19 pandemic significantly contributed to Ethiopia's preparedness and access to oxygen to treat COVID-19 patients during the early days of the pandemic.

While many countries later followed suite, CHAI's support to implement this in the years before the COVID-19 pandemic significantly contributed to Ethiopia's preparedness and access to oxygen to treat COVID-19 patients during the early days of the pandemic.

2017

Increasing access to cancer medications

CHAI announces an agreement with the American Cancer Society, Pfizer Inc., and Cipla Inc. to expand access to 16 essential cancer treatment medications, including chemotherapies, in Ethiopia, Kenya, Nigeria, Rwanda, Tanzania, and Uganda, where 44 percent of cancer cases in sub-Saharan Africa occur.

CHAI announces an agreement with the American Cancer Society, Pfizer Inc., and Cipla Inc. to expand access to 16 essential cancer treatment medications, including chemotherapies, in Ethiopia, Kenya, Nigeria, Rwanda, Tanzania, and Uganda, where 44 percent of cancer cases in sub-Saharan Africa occur.

2017

Affordable single-pill HIV regimen with DTG

CHAI and partners, including UNAIDS, the Bill & Melinda Gates Foundation, Unitaid, the United Kingdom’s Department for International Development, PEPFAR, USAID, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, announce a groundbreaking agreement with Aurobindo and Viatris to accelerate the availability of the first affordable, generic, single-pill HIV treatment containing DTG, a best-in-class HIV medication, to public sector purchasers in low- and middle-income countries at around US$75 per person, per year.

CHAI and partners, including UNAIDS, the Bill & Melinda Gates Foundation, Unitaid, the United Kingdom’s Department for International Development, PEPFAR, USAID, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, announce a groundbreaking agreement with Aurobindo and Viatris to accelerate the availability of the first affordable, generic, single-pill HIV treatment containing DTG, a be...

2018

Breakthrough pricing agreement for latest diagnostic technology

CHAI and partners, including United Kingdom’s Department for International Development (DFID), Unitaid, MedAccess (backed by the UK government), the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the African Society for Laboratory Medicine (ASLM), and the government of Zambia, reach a breakthrough pricing agreement with Hologic to significantly lower the cost of state-of-the art diagnostic testing for HIV, hepatitis, and cervical cancer in low-and middle-income countries at a price of US$12 per patient sample.

CHAI and partners, including United Kingdom’s Department for International Development (DFID), Unitaid, MedAccess (backed by the UK government), the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the African Society for Laboratory Medicine (ASLM), and the government of Zambia, reach a breakthrough pricing agreement with Hologic to significantly lower the cost of state-of-the ar...

2018

Lowering costs for lifesaving oxygen diagnostics

CHAI helps negotiate a 58 percent reduction, on average, for the price of handheld pulse oximeters — simple, life-saving tools that can help quickly diagnose severe pneumonia.

CHAI helps negotiate a 58 percent reduction, on average, for the price of handheld pulse oximeters — simple, life-saving tools that can help quickly diagnose severe pneumonia.

2019

Improving access to quality cancer treatment

CHAI forms Allied Against Cancer with the American Cancer Society, the National Comprehensive Cancer Network (NCCN), and IBM. NCCN adapts cancer-treatment guidelines for use in African hospitals and IBM develops an online tool to help African oncologists use the guidelines more efficiently.

CHAI forms Allied Against Cancer with the American Cancer Society, the National Comprehensive Cancer Network (NCCN), and IBM. NCCN adapts cancer-treatment guidelines for use in African hospitals and IBM develops an online tool to help African oncologists use the guidelines more efficiently.

2019

Expansion into cervical cancer

CHAI begins work to scale up safe, effective, and affordable cervical cancer screening and treatment of pre-cancerous legions across partner countries.

CHAI begins work to scale up safe, effective, and affordable cervical cancer screening and treatment of pre-cancerous legions across partner countries.

2020

Responding to the COVID-19 pandemic

CHAI helps countries secure affordable supplies to safely and effectively treat patients with COVID-19, including personal protective equipment, biomedical devices for oxygen therapy, and diagnostics. This includes a global partnership with Unitaid, Viatris, and Macleods to make available 120 million affordable, rapid diagnostic tests for low- and middle-income countries.

CHAI helps countries secure affordable supplies to safely and effectively treat patients with COVID-19, including personal protective equipment, biomedical devices for oxygen therapy, and diagnostics. This includes a global partnership with Unitaid, Viatris, and Macleods to make available 120 million affordable, rapid diagnostic tests for low- and middle-income countries.

2020

Price agreement drastically lowers cost for yearly pediatric HIV treatment

CHAI and Unitaid announce a groundbreaking agreement with two pharmaceutical companies, Viatris and Macleods, to reduce by 75 percent the cost of HIV treatment for children in low- and middle-income countries. The partnership resulted in the fastest ever U.S. regulatory approval for a generic pediatric HIV drug.

CHAI and Unitaid announce a groundbreaking agreement with two pharmaceutical companies, Viatris and Macleods, to reduce by 75 percent the cost of HIV treatment for children in low- and middle-income countries. The partnership resulted in the fastest ever U.S. regulatory approval for a generic pediatric HIV drug.

2021

Partnership makes dual rapid test for syphilis and HIV available for under US$1 in over 100 countries

CHAI, MedAccess, and SD Biosensor introduce new price for point-of-care rapid diagnostic test that enables simultaneous diagnosis of syphilis and HIV in under 20 minutes from a single finger-prick sample.

CHAI, MedAccess, and SD Biosensor introduce new price for point-of-care rapid diagnostic test that enables simultaneous diagnosis of syphilis and HIV in under 20 minutes from a single finger-prick sample.

2021

Unprecedented cooperation with global oxygen suppliers increases access and paves the way to address COVID-19

Agreement brokered by Unitaid and CHAI under the COVID-19 Oxygen Emergency Taskforce sees two of the world’s largest medical oxygen suppliers, Air Liquide and Linde, each collaborate with these ACT-Accelerator partners on increased access to oxygen.

Agreement brokered by Unitaid and CHAI under the COVID-19 Oxygen Emergency Taskforce sees two of the world’s largest medical oxygen suppliers, Air Liquide and Linde, each collaborate with these ACT-Accelerator partners on increased access to oxygen.

A woman in a wheelchair plays a game. Missing Billion report launched in October.

2021

CHAI partners with 10 country governments to increase access to assistive technology

Supporting global stakeholders under the UK Aid-funded AT2030 program, CHAI completed market analyses on wheelchairs, hearing aids, prosthetics, eyeglasses, and personal digital devices to understand interventions to support access and investment opportunities.

Supporting global stakeholders under the UK Aid-funded AT2030 program, CHAI completed market analyses on wheelchairs, hearing aids, prosthetics, eyeglasses, and personal digital devices to understand interventions to support access and investment opportunities.

A woman in a wheelchair plays a game. Missing Billion report launched in October.

2022

CHAI partners with governments to screen over one million women for cervical cancer

More than 80 percent of women received appropriate treatment across the program's 10 countries, with half of the countries exceeding 90 percent treatment coverage among women who screened positive for pre-cancerous legions.

More than 80 percent of women received appropriate treatment across the program's 10 countries, with half of the countries exceeding 90 percent treatment coverage among women who screened positive for pre-cancerous legions.

  • CHAI’s first program: HIV/AIDS
  • HIV first-line agreement
  • ART program in South Africa
  • Pediatric HIV treatment
  • HIV second-line agreement
  • Expansion into malaria
  • Scale-up HIV care and treatment in South Africa
  • Effective drugs to treat malaria
  • Expansion into vaccines
  • MATCH study launch
  • Expansion into human resources for health
  • Human resources for health in Zambia
  • Long-acting reversible contraception
  • Improving severe malaria testing and treatment
  • Treating childhood diarrhea
  • Ebola response in Liberia
  • Introducing new products to treat childhood diarrhea
  • Expansion into new programs
  • Reducing mother and infant deaths in Nigeria
  • Lowering the cost of hepatitis C treatment
  • Ethiopia develops first-of-its-kind medical oxygen roadmap in Africa
  • Increasing access to cancer medications
  • Affordable single-pill HIV regimen with DTG
  • Breakthrough pricing agreement for latest diagnostic technology
  • Lowering costs for lifesaving oxygen diagnostics
  • Improving access to quality cancer treatment
  • Expansion into cervical cancer
  • Responding to the COVID-19 pandemic
  • Price agreement drastically lowers cost for yearly pediatric HIV treatment
  • Partnership makes dual rapid test for syphilis and HIV available for under US$1 in over 100 countries
  • Unprecedented cooperation with global oxygen suppliers increases access and paves the way to address COVID-19
  • CHAI partners with 10 country governments to increase access to assistive technology
  • CHAI partners with governments to screen over one million women for cervical cancer
  • 2002
  • 2003
  • 2004
  • 2005
  • 2007
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022

Senior Leadership

Dr. Neil Buddy Shah

Chief Executive Officer

Rasha Hibri

Chief Financial Officer

Joshua Chu

Chief Operating Officer

Samantha Diamond

Vice President, Health Systems and NCDs

Dr. Olufunke Fasawe

Vice President, Integration

Dr. David Ripin

Executive Vice President, Infectious Diseases; Chief Science Officer

Leadership Council

Carolyn Amole

Vice President, HIV, Hepatitis, and Tuberculosis

Dr. Akudo Anyanwu

Vice President, Business Development

Dr. Rahel Belete

Vice President; Country Director – Ethiopia

Dr. Justin Cohen

Vice President, Global Malaria & NTDs

Harkesh Dabas

Managing Director, William J Clinton Foundation (Standing Invitee of CHAI India Affiliate)

Caitlin Glover

Vice President, Women's and Newborn Health

Zachary Katz

Vice President, Child Health

Neel Lakhani

Vice President, Innovation

Marie Chantale Lépine

Vice President, Global Markets

Gerald Macharia

Vice President, East and Southern Africa; Country Director - Kenya

Dang Ngo

Vice President, Southeast Asia, Pacific; Country Director, Vietnam

Board of Directors

President William J. Clinton

Board Member, Chair Emeritus & Co-Founder

Alan D. Schwartz

Chair of the Board & Chair of the Executive Committee

Raymond G. Chambers

Vice Chair of the Board

Bruce Lindsey

Board Member

Robert W. Selander

Board Member & Chair of the Finance Committee

Chelsea Clinton

Vice Chair of the Board & Co-Chair of HR Committee

Aliko Dangote

Board Member

Ann Veneman

Board Member

Dr. Mark Dybul

Board Member

Joy Phumaphi

Board Member & Co-Chair of HR Committee

Luis Alberto Moreno

Board Member

Ophelia Dahl

Board Member

Richard Zall

Board Secretary and Legal Counsel

Timothy A.A. Stiles

Board Member & Chair of the Audit Committee

Our Leadership Teams

Senior Leadership

Dr. Neil Buddy Shah

Chief Executive Officer

Trained as a physician and development economist, Dr. Neil Buddy Shah is an award-winning social entrepreneur, CEO, and global health funder who is passionate about making global health efforts as impactful as possible.

Dr. Shah was previously the Managing Director of GiveWell, a research and funding organization that directs hundreds of millions of dollars per year to programs in global health and development. GiveWell seeks to identify and fund the most cost-effective ways to save lives, and has recently emerged as one of the world’s largest private funders in global health.

Dr. Shah was previously co-founder, CEO, and now Board Chair of IDinsight, a global development data analytics and advisory firm with offices across Africa, Asia, and the US. At IDinsight, he helped pioneer the practical application of cutting-edge data and impact measurement tools such as randomized controlled trials, machine learning and results-based financing mechanisms to improve the impact of life-saving and antipoverty programs across Africa and Asia. Buddy worked previously at the World Bank and MIT’s Jameel Poverty Action Lab.

Buddy holds an AB in economics from Harvard, an MD with special distinction in global health policy from Einstein College of Medicine in New York, and an MPA in International Development from Harvard Kennedy School.

Dr. Shah is the Chair of Anthropic AI’s Long-Term Benefit Trust, and serves on the boards of Prevail Fund; the Institute to End Mass Incarceration at Harvard Law School; Educate Girls; Giving Green; and IDinsight. He was previously on the board at The Global Fund to Fight AIDS, Tuberculsosis, and Malaria. He is a term member of the Council on Foreign Relations, has served as guest faculty at Harvard Kennedy School and Stanford’s Graduate School of Business, and is a former Echoing Green Fellow and Forbes’ 30 under 30 Social Entrepreneur. He has lived and worked in India, Cambodia, Uganda, and the United States.

Rasha Hibri

Chief Financial Officer

Rasha Hibri is the Chief Financial Officer (CFO) at the Clinton Health Access Initiative, Inc (CHAI). She joined CHAI in 2020 and oversees CHAI’s global finance strategy and global financial operations including Budgets and Reporting, Business System Applications, Contracts, the International Controller’s Office (including Accounting, Payroll, and Accounts Payable), Internal Audit and Risk Management, Treasury, and Office Administration.

Prior to joining CHAI, Ms. Hibri was the CFO for India, Middle East and Africa for Allergan. In 2019, she was assigned as Acting Country Manager for India. From 2015 to 2018, Ms. Hibri was the CFO for the Middle East and North Africa region at British Telecoms Global Services. She has also worked as CFO for Eli Lilly and Company in the region and as Finance Director for Merck Sharp and Dohme (MSD), where she led growth initiatives and assessed customer needs, in addition to optimizing resource efficiency and effectiveness.

Joshua Chu

Chief Operating Officer

Joshua Chu is the Chief Operating Officer at the Clinton Health Access Initiative (CHAI). In this role, he oversees global operations, including Program Performance, Talent Development, Information Technology, Safeguarding and Operational Risk Management. He also leads cross-cutting initiatives to enhance organizational effectiveness and efficiency.

Mr. Chu joined CHAI in 2009, starting as the Deputy Country Director in Nigeria. He later took on the role of Senior Regional Program Director for Southeast Asia, where he successfully facilitated the development of new programs across Cambodia, China, Indonesia, Laos, Myanmar, Papua New Guinea, and Vietnam. As Executive Vice President of Vaccines and Non-Communicable Diseases (NCDs), Mr. Chu spearheaded efforts to improve immunization coverage, playing a key role in negotiating vaccine price reductions that resulted in over $1 billion in procurement savings for governments and global partners. He also led the development of CHAI’s newest programs for the prevention, diagnosis, and treatment of non-communicable diseases and expanded the use of assistive technologies for individuals with disabilities.

Before joining CHAI, Joshua held various key roles, including managing Singapore Airlines’ multi-billion dollar investment and fuel hedging portfolio. His extensive professional experience spans work in China, Malaysia, Nigeria, Singapore, the United States, and Zambia.

Mr. Chu earned his BS in Economics and BA in Middle Eastern and Asian Studies (summa cum laude) from the Wharton School of the University of Pennsylvania. He later obtained an MPhil in Development Studies (with distinction) from St. John’s College, University of Cambridge, as a Maxis Scholar.

Samantha Diamond

Vice President, Health Systems and NCDs

Samantha Diamond oversees CHAI’s work in health systems strengthening as well as non-communicable diseases. Ms. Diamond joined CHAI in 2011 to work with the Ministry of Health in Haiti on aid coordination and systems strengthening. She went on to play a key role in the expansion of CHAI’s work from HIV financing to sustainable health financing. She most recently served as Senior Director, Health Financing, working with CHAI offices, governments, and partners across Africa and Asia to address financial barriers to the availability and affordability of essential health services. Samantha holds an MPH and is an advanced DrPH candidate in health systems.

Dr. Olufunke Fasawe

Vice President, Integration

In her role as Vice President, Integration, Dr. Olufunke Fasawe plays a crucial role in the strategic alignment and coordination of various health programs and initiatives to ensure cohesive and efficient delivery of services in response to Governments’ priorities. In this role, she manages cross-functional teams, fosters partnerships to ensure that program objectives are met in line with CHAI’s mission and guiding principles to maximize impact.

Dr. Fasawe is committed to health equity and women’s and girls’ empowerment and is deeply passionate about improving healthcare services in Africa, particularly in Nigeria, where she led the CHAI’s SRMNH portfolio for almost a decade, also doubling as Director of Programs for the Nigeria office. Before joining CHAI in 2012, she worked as a health economics consultant at the Joint United Nations Programme on HIV/AIDS (UNAIDS) in Geneva.

Dr. Fasawe holds a Bachelor of Dental Surgery from the University of Lagos, Nigeria, a Master’s degree in International Health Management, Economics, and Policy from Bocconi University, Milan, Italy, and a Doctor of Public Health (DrPH) degree from the University of California, Berkeley. She also earned a professional certificate in Leadership, Engagement, Acceleration, and Disruption (LEAD) from Stanford University’s Graduate School of Business.

Dr. David Ripin

Executive Vice President, Infectious Diseases; Chief Science Officer

Dr. David Ripin leads efforts at CHAI to improve access to medicines and diagnostics for diseases like HIV, malaria, and tuberculosis, through sustainable market interventions. Under his leadership, CHAI has implemented agreements with pharmaceutical companies reducing prices of key drugs and diagnostics by up to 80 percent.

Joining CHAI in 2007, Dr. Ripin initially led the Pharmaceutical Sciences team, which was focused on reducing the cost of key drugs through recommending formulation, manufacturing process, and sourcing improvements, as well as conducting the transfer of these processes to manufacturing partners. Before joining CHAI, he worked at Pfizer, Inc., contributing to drug commercialization and manufacturing.

Dr. Ripin holds a Bachelor of Science in Chemistry and Asian Studies from Washington University in St. Louis and earned his Ph.D. in Chemistry from Harvard University.

Leadership Council

Carolyn Amole

Vice President, HIV, Hepatitis, and Tuberculosis

Carolyn has been at CHAI for 13 years, and prior to her current role she also worked in global market intelligence and led the country support team, while based in South Africa. A major focus of Carolyn’s career at CHAI is accelerating access to and uptake of drug and diagnostic innovations for people living with or at risk of HIV in low- and middle-income countries around the world.

Dr. Akudo Anyanwu

Vice President, Business Development

Dr. Akudo Anyanwu, an award-winning global health expert with over 20 years’ experience, joins CHAI from Texas Biomedical Research Institute, where she served as Vice President of Development. At Texas Biomedical, she led fundraising, forged strategic partnerships, and implemented a new advisory board and annual global health conference. Prior roles include Associate Dean of Development at Johns Hopkins University and Director of Partnerships at Emory University. She has a decade of experience in in Rwanda, Nigeria, and South Africa focusing on HIV, TB, and malaria programs. Dr. Anyanwu has also served on the boards of Roll Back Malaria, the Global Health Council, and the AIDS Healthcare Foundation. Dr. Anyanwu holds a doctorate in medicine from Tufts University, a master of public health from Harvard University’s School of Public Health, and a bachelor of science molecular biology from Lehigh University.

Dr. Rahel Belete

Vice President; Country Director – Ethiopia

Rahel Belete is the Vice President and Country Director of the Clinton Health Access Initiative (CHAI) Ethiopia who is responsible to lead and manage the Ethiopia office, strategically aligning the country’s programs with the overall CHAI program strategy, programmatic and financial planning/reporting, fundraising, and monitoring and evaluation efforts for all work areas. She manages relationships across all stakeholders ranging from Government leadership, Ministry technical experts, in country partners, to global counterparts within CHAI and donors.

Rahel joined CHAI in 2012 and prior to assuming her current role, she served as Senior Deputy Country Director in Ethiopia. During her tenure she diversified the donor mix, expanded programs scope to include new thematic areas such as essential treatment for diarrhea, oxygen and breast cancer. She has developed systems, procedures, protocols, provided leadership and management to the organization and align the strategic direction along with the government strategic priorities.

Prior to joining CHAI, she worked for Marie Stopes International- Tanzania for five years as a Deputy Country Director and spent eight years with DKT Ethiopia, leading the marketing and communication innovations of the varied social marketing programs and products.

Rahel holds a PhD from Bulacan State University of the Philippines in Business Administration, Masters in Organizational Leadership from Azusa Pacific University, California, MBA and BA from Pune University in India.

Dr. Justin Cohen

Vice President, Global Malaria & NTDs

Dr. Justin Cohen leads the malaria and neglected tropical disease program. Justin is an infectious disease epidemiologist who earned his doctorate in Epidemiological Science and MPH in International Health from the University of Michigan and studied Molecular, Cellular, and Developmental Biology at Yale University. He serves on the advisory board of the Malaria Atlas Project, was on the steering committee of the Gates Foundation’s Malaria Modeling Consortium, and co-authored WHO’s Framework for Malaria Elimination and Manual for Elimination Scenario Planning, amongst other guidance documents. He has published over 50 peer reviewed articles related to the theory and practice of malaria elimination and program optimization.

Harkesh Dabas

Managing Director, William J Clinton Foundation (Standing Invitee of CHAI India Affiliate)

Harkesh Dabas is Managing Director, William J Clinton Foundation (Standing Invitee of CHAI India Affiliate). In this role, he provides leadership and strategic direction to CHAI operations and partnerships in India. Previously, Mr. Dabas led CHAI’s Access program efforts in new initiatives and organizational engagement with manufacturers of generic ARVs as well as other drug and vaccines.

Prior to joining CHAI, Mr. Dabas served in the Indian Navy for over two decades in various leadership positions, including Joint Director of Operations at the Ministry of Defence, where he was responsible for the development and execution of strategic plans and policies. He also commanded an anti-submarine warfare corvette and served as the Secretary to the Commanders’ Conference, the Navy’s highest strategic decision-making body, wherein he was involved in the development of strategy across a broad spectrum of issues.

Mr. Dabas holds post-graduate degrees in Nautical Science and Operations, a Masters in Defence and Strategic Studies, and a Masters in Business Administration from the Indian Institute of Management, Ahmedabad.

Caitlin Glover

Vice President, Women's and Newborn Health

Caitlin Glover leads the Women’s and Newborn Health cluster, which strives to end preventable maternal and newborn mortality and increase access to contraception and high-quality reproductive health care. Caitlin is a public health leader with 15 years of experience developing and executing programs to improve the health of women and infants across more than 15 countries in Africa and Asia. Prior to joining CHAI, Caitlin spent extensive time in rural Kenya to help establish the Lwala Community Alliance, a community-led organization that aims to unlock the potential of communities to advance their own comprehensive well-being. Caitlin is a graduate of Dartmouth College and holds a master’s degree in public health from Columbia University. She is an active volunteer at Feeding Tampa Bay.

Zachary Katz

Vice President, Child Health

Zachary Katz is the Vice President of Child Health, leading CHAI’s efforts to prevent childhood mortality from preventable causes through its programming on diarrhea, pneumonia, vaccines, and nutrition. Zach also leads CHAI’s portfolio on access to oxygen. He joined CHAI in 2006, establishing its Papua New Guinea office and supporting the launch of the national pediatric HIV treatment program. Zach later managed CHAI’s programs in Cambodia and Southeast Asia, and later led the Laboratory Services team, expanding access to key HIV and tuberculosis diagnostics. From 2016 to 2020, he was the Chief Access Officer at the Foundation for Innovative New Diagnostics (FIND). Zach holds a BA in Geology from Carleton College and a Master’s in Public Administration from NYU. He is based in Geneva, Switzerland.

Neel Lakhani

Vice President, Innovation

Neel Lakhani has over a decade of experience propelling strategic innovation across the global health organization. During his 13-year CHAI tenure, Neel has been a leader in the Global Markets Team, negotiating agreements to accelerate access to top pharmaceutical products and developing innovative pricing that dramatically reduced the costs of essential health commodities. He currently leads CHAI’s Maximum Impact Incubator, which aims to scale the most highly cost-effective evidence-based interventions in public health. Neel is a Cornell University alumnus, holding an MBA and Master’s in Industrial and Labor Relations.

Marie Chantale Lépine

Vice President, Global Markets

Marie Chantale Lépine is a lawyer and former biopharmaceutical company executive. She joined CHAI’s Global Markets Team in 2015 as Special Advisor, spearheading various high impact market shaping initiatives. She now leads CHAI’s strategic market shaping undertakings across program areas, accelerating the development and market introduction of health products optimized for low- and middle-income country settings and creating sustainable marketplaces to increase equitable access to safe and efficacious health products in those settings.

Gerald Macharia

Vice President, East and Southern Africa; Country Director - Kenya

Gerald Macharia joined CHAI in 2005 to establish the organization’s Kenya office and now leads operations across Kenya, Lesotho, Malawi, Mozambique, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe. Previously, he served as CEO of Faulu Kenya, transforming the small NGO program into one of East Africa’s leading microfinance institutions. His innovative work with the Vodafone Group helped pioneer the award-winning M-Pesa money transfer system. Mr. Macharia has held key roles in various microfinance associations and currently serves on the board of Kenya’s Micro Enterprise Support Program Trust. He holds degrees from Kenyatta University, the Chartered Institute of Marketing (UK), Edinburgh Business School, Moi University School of Business & Economics, and has completed Stanford University’s Graduate School of Business Program of Strategy & Organization.

Dang Ngo

Vice President, Southeast Asia, Pacific; Country Director, Vietnam

Dang Ngo is the Vice President for Asia Pacific, overseeing operations and strategic priorities in Cambodia, China, Laos, Indonesia, Myanmar, Papua New Guinea, and Vietnam, and covering initiatives including hypertension, diabetes, cancer, HIV, TB, malaria, hepatitis, vaccines, sexual and reproductive health, assistive technologies, laboratory system, primary health care, and health information systems. Mr. Ngo is also CHAI’s Country Director in Vietnam, leading a high-performing team to significant successes including scaling up of HIV treatment coverage for children from 9 percent in 2006 to 86 percent in 2015, screening over 1.2 million presumptive TB cases and referring thousands to treatment via the CHAI-developed ACIS mobile platform, adding hepatitis C treatment to the social health insurance, accelerating malaria elimination from 15,752 cases in 2014 to 448 cases in 2023, among others.

Mr. Ngo joined CHAI in 2008 as a Program Coordinator in Vietnam and assumed the Deputy Country Director and Country Director roles in 2010 and 2011, respectively. He is also a member of CHAI’s Leadership Council.

Prior to joining CHAI, Mr. Ngo developed a landmine risk prediction model using statistical tools that changed the UN Mine Action Centre’s approach to reducing landmine incidences in Afghanistan. Additionally, he led the development of market-leading enterprise-level educational tools and websites to link students to universities. He is also an award-winning photographer.

Board of Directors

President William J. Clinton

Board Member, Chair Emeritus & Co-Founder

Alan D. Schwartz

Chair of the Board & Chair of the Executive Committee

Raymond G. Chambers

Vice Chair of the Board

Bruce Lindsey

Board Member

Robert W. Selander

Board Member & Chair of the Finance Committee

Chelsea Clinton

Vice Chair of the Board & Co-Chair of HR Committee

Aliko Dangote

Board Member

Ann Veneman

Board Member

Dr. Mark Dybul

Board Member

Professor Dame Sally Davies

Board Member

Joy Phumaphi

Board Member & Co-Chair of HR Committee

Luis Alberto Moreno

Board Member

Ophelia Dahl

Board Member

Richard Zall

Board Secretary and Legal Counsel

Timothy A.A. Stiles

Board Member & Chair of the Audit Committee

Join Our Team

CHAI is looking for dynamic and self-motivated individuals who are committed to strengthening health systems around the world and expanding access to care and treatment of HIV/AIDS, malaria, and other illnesses.

Back To Top